Roche to complete acquisition of U.S. biopharma company Poseida
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue…
9,510$
-0,52%
Echtzeit-Aktienkurs Poseida Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Poseida Therapeutics Inc. Aktie
Roche set to finalise $1.5bn Poseida Therapeutics takeover
Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on…
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for…
PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors
…
Poseida Therapeutics Aktie: Tolle Perspektiven für Anleger!
Die Poseida Therapeutics Aktie verzeichnete im November 2024 eine bemerkenswerte Entwicklung an den Börsen. Mit einem aktuellen Kurs von 9,31…
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this…
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities
…
Pharma-Deal: Roche baut Zelltherapie mit Übernahme von US-Biotechfirma aus
Der Schweizer Konzern will Poseida Therapeutics um bis zu 1,5 Milliarden Euro aufkaufen. Das kalifornische Unternehmen arbeitet unter anderem an Therapien…
Roche to acquire Poseida Therapeutics for $1.5bn
…
Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion
…
Roche to acquire US-based Poseida Therapeutics By Reuters
Roche to acquire US-based Poseida Therapeutics…
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.…
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
…
Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful
…
Poseida Therapeutics: Why I Am Still Holding On To The Stock Into 2024 (Rating Downgrade)
…
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023.…
XFRA : 2RZ: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
XFRA : 2RZ: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …
Poseida jumps on $50M investment from Astellas
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Poseida Therapeutics Shares Leap on Astellas Investments >PSTX
Poseida Therapeutics Shares Leap on Astellas Investments >PSTX...…
Poseida Therapeutics in $50 Million Investment Deal With Astellas >PSTX
Poseida Therapeutics in $50 Million Investment Deal With Astellas >PSTX...…
XFRA : INSTRUMENT_SUSPENSION - US73730P1084
Instrument ID [4168170] (2RZ - US73730P1084) suspended...…
Form 8-K Poseida Therapeutics, For: Aug 04
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Poseida gains on FDA nod to start trials for CAR-T therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Poseida Therapeutics to join Russell 3000 and Russell 2000 indexes
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Poseida Therapeutics, For: May 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings…
Poseida Therapeutics: Q1 Earnings Insights
read more...…
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023
Highlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema, Ph.D., as President,…
Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors
SAN DIEGO, April 13, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing…
Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy
SAN DIEGO, April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing…
Form 8-K Poseida Therapeutics, For: Mar 27
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pre-market Movers: PSTX, NYCB, CVRX, FRC, PACW.
BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Mondays pre-market trading (as of 07.45…
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022.…
Poseida Therapeutics GAAP EPS of -$0.39 misses by $0.56, revenue of $10.05M misses by $21.7M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-K Poseida Therapeutics, For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022
Presented early data from Phase 1 trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 allogeneic CAR-T cell therapy programs at the European Society…
Form 8-K Poseida Therapeutics, For: Mar 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Poseida stock falls ~8% postmarket after founder, executive chairman to step down
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Poseida Therapeutics, For: Jan 26
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Poseida Therapeutics Announces Board Change
Eric Ostertag, M.D., Ph.D., Founder and current Executive Chairman, to retire from the Board of Directors and remain a consultant…
Poseida Therapeutics Ushers New Era For Gene Therapies, Analyst Initiating Coverage Says
Latest Ratings for PSTX
DateFirmActionFromTo Jan 2022Cantor FitzgeraldInitiates Coverage OnOverweight May 2021BTIGInitiates Coverage OnBuy Aug 2020B of A SecuritiesInitiates…